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Abstract 
Background: Renal cell carcinoma (RCC) is known to express CXCR3. The function of 
CXCR3 on RCC has not been clarified. The aims of this study were to reveal the 
function of CXCR3 on RCC and to investigate the regulating factors of CXCR3. 
Methods: Fifty-six clinical samples of clear cell RCC and corresponding normal renal 
tissue samples were obtained from surgical specimens of Japanese patients who 
underwent radical nephrectomy at Chiba University Hospital between 2000 and 2011. 
As RCC cell lines, 786-O, ACHN, and Caki-1 were used. The expression profile of 
CXCR3 and its splice variants were examined. For functional analyses, 786-O and 
IFN-γ-inducible 10-kDa protein or IP-10 (CXCL10) were selected as the representative. 
Results: CXCR3 and its ligands were abundant in RCC samples compared with 
corresponding normal kidney samples. The CXCR3-A/CXCR3-B ratio was 1.5 times 
higher in RCC samples than in normal kidney samples. CXCL10 treatment induced 
786-O cell migration and invasion; these effects were inhibited by neutralizing antibody. 
The expressions of phosphorylated RhoA and pro/active MMP-9 were up-regulated by 
CXCL10 treatment. In clinical samples, the expressions of CXCR3 and CXCR3-A were 
significantly higher in metastatic RCC than in non-metastatic RCC. Finally, the 
expression of CXCR3 and hypoxia-inducible factor 1 alpha (HIF-1-alpha) were 
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significantly correlated in the clinical samples. Regarding 786-O, the treatment with 
cobalt chloride (CoCl2) up-regulated CXCR3 and HIF-1-alpha expression 4.5-fold and 
2.2-fold, respectively. 
Conclusions: CXCR3 plays important roles in RCC metastasis. The expression of 
CXCR3 may be regulated by hypoxia.  
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Introduction 
Renal cell carcinoma (RCC) accounts for up to approximately 3% of new cancer cases 
and deaths in the Western world. At presentation, 20-30% of all RCC patients are 
diagnosed with metastatic disease [1]. In addition, 30-35% of RCC patients who 
undergo nephrectomy will experience relapse and develop metastatic RCC (mRCC) [2]. 
For patients with mRCC, the prognosis is extremely poor. Although many studies are 
being conducted with the aim of revealing the mechanisms of RCC metastasis, these 
mechanisms have not yet been well documented. 
Chemokines are a superfamily of small (7- 16 kDa), pro-inflammatory chemoattractant 
cytokines, which were originally characterized by their ability to induce migration of 
leukocytes [3, 4]. Recently, chemokines have also been demonstrated to play a major 
role in tumor metastasis [5-9]. Many kinds of cancers are found to express chemokine 
receptors, and their corresponding ligands are expressed by the sites of tumor 
metastases [5, 8, 10, 11].
 
    
Over 50 chemokines and 20 chemokine receptors have been identified so far. The 
chemokine receptors are divided into four subgroups (CXC, CC, CX3C, and C) 
depending on the position of the conserved cysteine residues from the amino terminal 
end of these proteins [12]. CXCR3 is one of the relatively well-documented subgroups, 
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a classic seven-transmembrane G-protein-coupled CXC chemokine receptor which has 
been reported to be expressed on activated T lymphocytes [13]. CXCR3 has been 
observed to induce calcium flux and chemotaxis in response to its ligands, monokine 
induced by human interferon-gamma (IFN-γ) or Mig (CXCL9), IFN-γ-inducible 10-kDa 
protein or IP-10 (CXCL10), and interferon-inducible T-cell alpha chemoattractant or 
I-TAC (CXCL11) [14].   
In a previous study, we first reported that CXCR3 is expressed in RCC, and we 
indicated that CXCR3 should play an important role in tumor metastasis [15]. To date, a 
few reports have become available discussing the relationship between RCC and 
CXCR3 [16-18], but the function of CXCR3 in RCC metastasis has not yet been 
revealed. To clarify the function of CXCR3 in RCC metastasis, we evaluated the 
expression of CXCR3 in various RCC clinical samples and performed in vitro assays 
using human RCC cell lines.  
Using clinical samples, we demonstrated the relationship between CXCR3 and RCC 
metastasis. We also revealed that the CXCR3/CXCL10 axis induced tumor migration 
and invasion. Furthermore, we investigated the mechanism of how the 
CXCR3/CXCL10 axis induced cell migration and invasion, and how the expression of 
CXCR3 is regulated.  
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Material and Methods 
Clinical samples 
Fifty-six clinical samples of clear cell RCC and corresponding normal renal tissue 
samples were obtained from surgical specimens of Japanese patients who underwent 
radical nephrectomy at Chiba University Hospital between 2000 and 2011. None of the 
patients had received adjuvant therapy before surgery. Written informed consent was 
preoperatively obtained from each patient. Parts of the tissues were frozen immediately 
with liquid nitrogen and were kept at -80C until analysis. The remaining tissues were 
fixed with 10% formalin and embedded in paraffin. Hematoxylin and eosin staining was 
also performed. The clinicopathological features of the patients with clear cell RCC are 
detailed in Table 1. 
Cell lines, cell culture, and treatment with cobalt chloride 
The cell line 786-O was from American Type Culture Collection (ATCC
®
 Manassas 
VA, USA), and the cell lines ACHN and Caki-1 were supplied from The Cell Resource 
Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku 
University (Sendai, Miyagi, Japan). Authentication of cell lines was achieved by Short 
Tandem Repeat profiling. These cell lines were passaged in our laboratory for fewer 
than 6 months after resuscitation. These cell lines were cultured in RPMI-1640 medium 
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supplemented with 10% fetal bovine serum (FBS), and were maintained in an incubator 
with a humidified atmosphere of 95% air and 5% CO2 at 37C. To induce chemical 
hypoxia, 500 μM of cobalt chloride (CoCl2) was added to the medium and the cells 
were treated for 24 hours. 
Real-time reverse-transcription polymerase chain reaction (RT-PCR) analysis 
Total RNA was extracted from the frozen surgical specimens and cell lines using the 
RNeasy Mini Kit (QIAGEN, Venlo, Netherlands) according to the manufacturer’s 
instructions. Complementary DNA was synthesized using the ImProm-II
TM
 Reverse 
Transcription System with random primer (Promega, Tokyo, Japan). Real-time RT-PCR 
was performed using an ABI7300 Real-Time PCR System (Applied Biosystems, 
Carlsbad, CA, USA). The PCR reactions were performed in a final volume of 25 μL of 
a reaction mixture of SYBR
®
 Green PCR Master Mix (Applied Biosystems). Conditions 
for real-time RT-PCR were as follows: at 50C for 2 minutes, at 95C for 10 minutes, 40 
cycles at 95C for 15 seconds, and at 60C for 1 minute. The mRNA levels of tested 
genes were normalized to β-actin levels using a ΔCt method. In clinical samples, the 
mean expression ratios for tumor specimens were normalized with respect to the mean 
expression ratios for normal renal tissues. The primers for human CXCR3 were 
5’-AGCTCTGAGGACTGCACCAT-3’ and 5’-CAGTCACTGCTGAGCTGGAA-3’; for 
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human CXCR3A, 5’-CCATGGTCCTTGAGGTGAGT-3’ and 
5’-CAGCAGAAAGAGGAGGCTGT-3’; for human CXCR3B, 
5’-TGCCAGGCCTTTACACAGC-3’ and 5’-TCGGCGTCATTTAGCACTTG-3’; for 
human CXCL9, 5’-CCACCGAGATCCTTATCGAA-3’ and 
5’-CTAACCGACTTGGCTGCTTC-3’; for human CXCL10, 
5’-GCAGAGGAACCTCCAGTCTCA-3’ and 5’-GCAGGTACAGCGTACGGTTC-3’; 
for human CXCL11, 5’-GGTGGGTGAAAGGACCAAAA-3’ and 
5’-CCGATGGTAACCAGCCTTTC-3’; for human hypoxia-inducible factor 1-alpha 
(HIF-1α), 5’-CCCAATGGATGATGACTTCC-3’ and 
5’-TGGGTAGGAGATGGAGATGC-3’ and for human β-actin, 
5’-CTCCTCCTGAGCGCAAGTACTC-3’ and 5’-TCCTGCTTGCTGATCCACATC-3’. 
Reagents and antibodies 
Recombinant CXCL10 was purchased from R&D Systems (Minneapolis, MN, USA). 
Anti-CXCR3 and anti-pro/active matrix metalloproteinase-9 (MMP9) monoclonal 
antibodies (mAbs) were obtained from R&D Systems. Anti-Rho A and 
anti-phospho-Rho A (pSer188) were obtained from ABGENT (San Diego, CA, USA) 
and ECM Biosciences (Versailles, KY, USA). 
Western blot analysis 
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Cells incubated on dishes were lysed with radioimmunoprecipitation assay (RIPA) 
buffer (150 mmol/L NaCl, 50 mmol/L Tris (pH 8.0), 0.5% deoxycholic acid, 1% NP-40 
and 1 mmol/L phenylmethylsulfonyl fluoride). Protein samples (30 μg) were subjected 
to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to Hybond-C membranes (GE Healthcare, Little Chalfont, UK). The 
membranes were blocked in 5% milk TBS-T (tris-buffered saline (TBS) containing 
0.05% Tween
®
 20; 1 hour at room temperature), and, following incubation with the 
respective primary antibody (1:100 dilution, overnight at 4C), membranes were 
exposed to species-specific horseradish peroxidase-labeled secondary antibodies. 
Signals were detected using the ECL Plus Western Blotting Detection System (GE 
Healthcare) and visualized using LAS-4000 mini software (Fujifilm, Tokyo, Japan). 
Immunohistochemistry 
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded sections 
using anti-CXCR3 mAbs. Briefly, after deparaffinization and hydration, the slides were 
treated with endogenous peroxidase in 0.3% hydrogen peroxide solution in 100% 
methanol for 30 minutes, after which the sections were blocked for 2 hours at room 
temperature with 1.5% blocking serum in PBS before reacting with anti-CXCR3 mAbs 
(1:100 dilution) at 4C in a moist chamber overnight. Following incubation with the 
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primary antibody, the specimens were washed three times in PBS and were then treated 
with the EnVision
TM
 (Dako, Glostrup, Denmark) reagent followed by color 
development in 3,3’-diaminobenzidine tetrahydrochloride (Dako, Carpinteria, CA). 
Finally, the slides were lightly counterstained with hematoxylin, dehydrated with 
ethanol, cleaned with xylene, and mounted. 
Wound healing assay 
Cultured monolayers of 786-O cells were wounded with a pipette tip and cultured for a 
further 16 hours in starvation medium with a different concentration of CXCL10. PBS 
was used as negative control. The cells were visualized by light microscopy at 0 and 16 
hours after scratch. The migration rate was calculated using Lenaraf220b software 
(Atelier M&M, Japan) by measuring the distance traveled by the cells, using the 
following formula: migration rate = distance from the edge (0 hour) – the distance from 
the edge (16 hours)/ the distance from the edge (0 hour). All experiments were repeated 
four times. 
Migration assay 
Migration was assayed in 24-well Transwell cell culture chambers (8-μm pores; Coster, 
Cambridge, MA, USA). After 786-O cells were added to the upper chamber (5×10
4
 
cells/well) and incubated for 8 hours, cells attached on the lower surface of the 
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membrane were counted in at least five fields (original magnification, 200×). PBS was 
used as negative control. At least three experiments were performed for each set. For 
neutralization studied, cells were incubated with anti-CXCR3 mAb in the upper 
chamber. 
Invasion assay 
Invasion was assayed in 24-well BD BioCoat
TM
 Matrigel
TM
 Invasion Chambers (BD 
Biosciences, Franklin Lakes, NJ, USA). After 786-O cells were added to the upper 
chamber (5×10
4
 cells/well) and incubated for 16 hours, cells attached on the lower 
surface of the membrane were counted in at least five fields (original magnification, 
200×). PBS was used as negative control. At least three experiments were performed for 
each set. For neutralization studied, cells were incubated with anti-CXCR3 mAb in the 
upper chamber. 
Statistical analysis 
Values were expressed as the mean ± standard error. The Mann-Whitney U test and the 
Wilcoxon signed-rank test were used for statistical evaluation of real-time PCR data. 
Statistical significance was defined as P < 0.05. All statistical analyses were performed 
using SAS version 9.2 software (SAS Institute, Cary, NC, USA). 
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Results 
CXCR3 and its splicing variant expression on clinical samples and on RCC cell 
lines  
In our previous study, we revealed that RCC expressed CXCR3. In the present study, 
we examined the expression of CXCR3 and its splicing variants CXCR3-A and 
CXCR3-B in clinical samples by real time RT-PCR. The expression of CXCL9, 
CXCL10 and CXCL11 were also examined. The patients’ characteristics are listed in 
Table 1. All patients had been diagnosed with clear cell RCC. At the time of the surgery, 
15 patients had metastases and 41 patients had no metastasis. We confirmed that the 
expression of CXCR3 and its ligands are highly up-regulated in renal cancer tissues 
compared with adjacent normal kidney tissues (Fig. 1A). The expression levels of 
CXCR3, CXCL9, CXCL10 and CXCL11 in RCC tissues were about 6 times greater, 12 
times greater, 22 times greater, and 8 times greater, respectively, compared with the 
levels in the corresponding normal kidney tissues.  
The expression ratio of CXCR3-A/CXCR3-B was also calculated. The average 
CXCR3-A/CXCR3-B ratio was 1.48 in renal cancer tissues and 1.01 in normal kidney 
tissues. In cancer tissues, the dominance of CXCR3-A expression was demonstrated by 
immunohistochemistry; we confirmed that CXCR3 expression was coincident with the 
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RCC cell membrane (Fig. 1B). The antibody used for immunohistochemistry could not 
distinguish between CXCR3-A and CXCR3-B. According to the real-time RT-PCR 
results, more than three-fifths of the staining could be considered as CXCR3-A. 
As the next step, we examined the expression of CXCR3 on RCC cell lines. By real 
time RT-PCR, we confirmed that RCC cell lines expressed CXCR3, and the highest 
expression was observed on the 786-O cell line (Fig. 1C). Then, we investigated the 
protein expression level of CXCR3 (Fig. 1D) by Western blot analysis. At the protein 
level, the 786-O cell line was proved to express CXCR3 at the highest level among the 
three study cell lines (Fig. 1D). Moreover, the CXCR3-A/CXCR3-B expression ratio 
was equivalent in the 786-O cell line and in the clinical samples. The 
CXCR3-A/CXCR3-B ratio on the 786-O cell line was 1.7. For these reasons, we 
selected the 786-O cell line for further analysis. We next examined whether 786-O 
secreted CXCL9, CXCL10 and/or CXCL11. Examination by enzyme-linked 
immunosorbent assay (ELISA) using 786-O culturing supernatant revealed that 786-O 
did not secrete any of the three ligands CXCL9, CXCL10 or CXCL11 (data not shown). 
CXCL10 induced RCC cell line migration and invasion 
CXCR3 has three ligands: CXCL9, CXCL10, and CXCL11. It is thought that there is 
no functional difference between these three ligands. In clinical samples, CXCL10 was 
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the highest expressed ligand among these three. We therefore selected CXCL10 as the 
representative ligand for functional analysis.  
For functional analysis of the CXCR3/CXCL10 axis, we first examined the 
proliferation of 786-O treated with CXCL10. The cell line 786-O was cultured with or 
without various concentrations of CXCL10, and CXCL10 did not alter cell proliferation 
(data not shown). Then, we conducted migration analyses using a wound healing assay 
and a migration assay kit. Migration of 786-O increased 1.8-fold with CXCL10 
treatment, in comparison with control. Migration change was observed in a 
concentration-dependent manner, with the maximum effect observed in 100 ng/mL of 
CXCL10 (Fig. 2A). For further analysis, the concentration of CXCL10 was fixed at 100 
ng/mL. Using a migration assay kit, a similar result was obtained (Fig. 2B); CXCL10 
treatment up-regulated 786-O migration activity approximately 1.7-fold, and 
neutralizing the CXCR3 antibody inhibited its effect. Then, we examined whether 
CXCL10 treatment would influence the invasion of 786-O. Using an invasion assay kit, 
CXCL10 treatment up-regulated invasion activity approximately 1.8-fold; its effect was 
also inhibited by the neutralizing CXCR3 antibody (Fig. 2C). 
Moreover, in analyses of clinical samples, the relative expression level of CXCR3 
(tumor/normal) was as much as 3 times higher in the patients with metastases compared 
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with the patients without metastasis (P <0.05) (Fig. 2D (1)). The CXCR3-A/CXCR3-B 
ratio in the metastasis group was also significantly higher compared with the 
non-metastasis group (P <0.05) (Fig. 2D (2)).  
How migration and invasion were induced 
To investigate the mechanisms of how the CXCR3/CXCL10 axis promoted cell 
mobility, we first studied the expression change of phosphorylated RhoA. Adding 
CXCL10 increased the expression of phosphorylated RhoA. The expression increased 
from 5 minutes to 10 minutes after treatment; then it began to decrease gradually to 30 
minutes after treatment (Fig. 3A).  
Second, we examined pro/active MMP-9 induction by CXCL10 treatment. Under 
general conditions, 786-O does not secrete pro/active MMP-9. After treatment with 
CXCL10 for 24 hours, we detected pro/active MMP-9 expression in culturing 
supernatant by Western blotting. The strongest expression was observed at the 
100-ng/mL concentration of CXCL10 (Fig. 3B).  
Hypoxia induced CXCR3 expression 
The expression level of CXCR3 and HIF-1-alpha was significantly correlated in 
clinical samples at the mRNA level (Fig. 4A). This result suggested that HIF-1-alpha 
might regulate CXCR3 expression.  
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To confirm this suggestion, we treated the three RCC cell lines (786-O, Cali-1, and 
ACHN) with cobalt chloride (CoCl2), which mimics a low-oxygen condition. After 
CoCl2 treatment, CXCR3 and HIF-1-alpha expression were induced only in the 786-O 
cell line; the expression of CXCR3 and HIF-1-alpha was up-regulated 4.5-fold and 
2.2-fold after treatment (Fig. 4B). In Caki-1 and ACHN, the expression of CXCR3 and 
HIF-1-alpha was not induced. One of the fundamental differences between 786-O and 
the other two cell lines is in their type of von Hippel-Lindau (VHL) protein. The cell 
line 786-O has the mutated VHL protein; in contrast, Caki-1 and ACHN have the 
wild-type VHL protein. Wild-type VHL protein acts to prevent HIF-1-alpha 
accumulation; this is the reason why CoCl2 induced CXCR3 and HIF-1-alpha 
expression only in the 786-O cell line.  
 
17 
 
Discussion 
CXCR4 is known as one of the key players in RCC metastasis [16].
 
As for CXCR3, 
there have been several studies that examined CXCR3 and its relationship to RCC 
metastasis, and most of the reports considered CXCR3 as a favorable prognostic factor 
[17, 18]. In these reports, CXCR3 was considered to prevent cancer progression. On the 
other hand, in other types of the cancers, CXCR3 is considered as a poor prognostic 
factor, and one which promotes cancer metastasis [19-25]. CXCR3 is known to have at 
least two splice variants, CXCR3-A and CXCR3-B [26, 27]. In most of the previous 
reports discussing CXCR3 and cancer prognosis, the expression ratio of 
CXCR3-A/CXCR3-B was not mentioned. CXCR3-A has been shown to prompt cell 
proliferation and migration, whereas CXFR3-B has been shown to inhibit cell migration 
and induce apoptosis [26-28]. In in vitro analyses of RCC, CXCR3-B has been shown to 
work as a tumor suppresser [28-30]. The CXCR3-A/CXCR3-B ratio is important for 
determining tumor destiny.  
Because reliable CXCR3-isoform specific antibodies are not available, we used 
real-time RT-PCR to quantify the expression level of these two splice variants. In the 
present study, we showed that CXCR3-A was more abundant than CXCR3-B in clinical 
renal cancer samples, and the same dominancy of CXCR3-A was observed in the 786-O 
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cell line. Under such conditions, we showed that CXCR3 expression was significantly 
related to metastasis in clinical samples, and the CXCR3/CXCL10 axis played an 
important role in tumor metastasis in vitro using the 786-O cell line.  
There have been a few reports which discuss the relationship between CXCR3 and 
hypoxia. Only in the breast cancer cell line, CXCR3 expression was reported to be 
regulated by CXCL10, which is induced by hypoxia [31].
 
As far as we know, the 
present study is the first report to reveal the relationship between CXCR3 and hypoxia 
both in vitro and in clinical samples of RCC.  
Furthermore, in our previous study, we revealed that tumor-associated macrophages 
(TAM) express CXCR3 [15]. TAMs are now well-recognized as promoting tumor 
progression [32]. TAMs are recruited to the ligands’ rich tumor sites, and help tumors to 
progress. These results shed new light on the mechanisms of how the microenvironment 
promotes tumor metastasis.  
CXCR3 has the potential to be a candidate for a new therapy target because of its 
important roles in cancer progression. Although CXCR3 is reported to work as a 
regulator of inflammation, the immune reaction and angiogenesis [3, 4], the functions of 
CXCR3 are generally not necessary to maintain usual human activities. Moreover, it is 
easy to inhibit its functions by using the neutralizing CXCR3 antibody. CXCR3 is 
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considered to fulfill the requirements for the essential conditions as a molecular therapy 
target. 
In three measured chemokines, CXCL10 has been observed to be the most abundant 
in clinical cancer tissues. Using ELISA, we examined whether we could measure 
CXCL10 expression in human serum. We could detect CXCL10 expression at a 
concentration similar to that used for experiments (50 ng/mL - 200 ng/mL) in clinical 
human serum. The expression level of CXCL10 was significantly correlated with the 
expression level of CXCR3-A (data not shown). CXCL10 is a potent tumor marker 
which predicts tumor metastasis and prognosis. Actually, in head and neck lymphoma, 
serum CXCL10 has well-reflected patients’ disease status [33]. As the next step, we are 
preparing to test serum CXCL10 expression as a tumor marker for predicting tumor 
prognosis. 
In conclusion, the present study clarified the important role of the CXCR3/CXCL10 
axis in tumor metastasis, and in CXCR3/CXCL10 interaction-induced cell migration 
and invasion. Hypoxia was indicated as regulative of CXCR3 expression. 
CXCR3/CXCL10 has the potential to be a target of new therapy. It is a candidate for 
becoming a novel biomarker that can be easily accessed in daily clinical situations.  
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Table 1: Characteristics of the study subjects with clear cell renal cell carcinoma 
(RCC) 
Pathologic T stage N 
Nuclear 
grade 
n 
Metastasis 
at surgery 
n 
pT1a 20 G1 11 M0 41 
pT1b 13 G2 39 M1 15 
pT2 7 G3 6   
pT3a 9     
pT3b 6     
pT3c 1     
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FIGURE LEGENDS  
Figure 1. Expression of CXCR3 and its ligands in clinical samples and RCC cell 
lines. A: The expression of CXCR3 and its ligands at the mRNA level in clinical 
samples. CXCR3 and its ligands are more abundant in tumor tissues (T) than 
corresponding normal tissues (N). *: P < 0.01. B: The localization of CXCR3 was 
examined by immunohistochemistry. (a) Hematoxylin and eosin (HE) staining of clear 
cell RCC (x200). (b) Immunohistochemistry of CXCR3 (x200). CXCR3 expression was 
coincident with cell membrane. C: CXCR3 mRNA expression in RCC cell lines. The 
expression of CXCR3 was approximately 3 times greater on 786-O compared with 
ACHN and Caki-1 at the mRNA level. D: CXCR3 protein expression in RCC cell lines. 
At the protein level, 786-O was proved to express CXCR3 at the highest level among 
these 3 cell lines.  
 
Figure 2. Effect of CXCL10 on 786-O. A: Migration analysis using wound healing 
assay. (a) Pretreatment with phosphate buffered saline (PBS) (Control), (b) After 16 
hours (Control), (c) Pretreatment with 100 ng/mL of CXCL10, (d) After 16 hours (100 
ng/mL of CXCL10) The percentages of the scratched wounds’ fulfillment are presented 
as a bar graph. CXCL10 treatment induced cell migration in a concentration-dependent 
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manner. The influence reached a plateau at the 100 ng/mL concentration. B: Migration 
assay (original magnification, 200×). (a) Treatment with PBS, (b) Treatment with 100 
ng/mL of CXCL10, (c) Treatment with PBS after neutralization, (d) Treatment with 100 
ng/mL of CXCL10 after neutralization. The 100 ng/mL of CXCL10 induced 786-O cell 
migration, as we observed in the wound healing assay. This effect was inhibited by 
neutralizing antibody. The numbers of counted cells are displayed on the x-axis of the 
bar graph. C: Invasion assay (original magnification, 200×). (a) Treatment with PBS, (b) 
Treatment with 100 ng/mL of CXCL10, (c) Treatment with PBS after neutralization, (d) 
Treatment with 100 ng/mL of CXCL10 after neutralization. The 100 ng/mL of CXCL10 
induced 786-O cell invasion by the same degree as migration. This effect was also 
inhibited by neutralizing antibody. D (1): Relative expression of CXCR3 in clinical 
samples. Expression of CXCR3 was significantly higher in patients with metastasis 
(M1) than without metastasis (M0) (*: P <0.05). D (2): The expression ratio of 
CXCR3-A/CXCR3-B was also higher in M1 patients than M0 patients (*: P <0.05). 
 
Figure 3. Mechanisms of induction of cell mobility. A: Total amount of RhoA and the 
phosphorylation status of RhoA (Ser-188) were measured by Western blot analysis after 
the treatment with 100 ng/mL CXCL10. The expression of phosphorylated RhoA 
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(P-RhoA) increased from 5 to 10 minutes after treatment, then it began to decrease 
gradually by 30 minutes. The expression of the total amount of RhoA did not change. B: 
Pro/active MMP-9 was measured by Western blot analysis after 48 hours treatment. 
Pro/active MMP-9 was secreted in culturing supernatant. The strongest expression was 
observed at the 100ng/mL concentration of CXCL10. 
 
Figure 4. A: The relationship between CXCR3 and HIF-1-alpha expression in clinical 
samples. The expression of CXCR3 and HIF-1-alpha was significantly correlated by 
real time RT-PCR. B: Expression changes of CXCR3 and HIF-1-alpha on 786-O cells 
after CoCl2 treatment. CoCl2 treatment, which mimicked hypoxia, induced CXCR3 and 
HIF-1-alpha expression on 786-O cells. The expression of CXCR3 and HIF-1-alpha was 
up-regulated 4.5-fold and 2.2-fold, respectively. 
 
 
 
 
 
 
29 
 
 
 
 
 
 
 
30 
 
 
 
 
 
 
 
31 
 
 
 
 
 
32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cancer 
平成 25年 10 月 23 日 投稿中 
 
